PMID

Data

Article Title

Organization

Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.

The University Of Queensland

Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.

Vanderbilt University

Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.

Ferring Research Institute

A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus.

Peking University

Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.

The University Of Queensland

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

Novo Nordisk

Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.

University Of Queensland

Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.

Dainippon Sumitomo Pharma

Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).

Vanderbilt University School Of Medicine

The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.

Merck Research Laboratories

A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.

Tufts University

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

Pfizer

Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.

Merck Research Laboratories

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

Indiana University

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

Bristol-Myers Squibb

Small-molecule agonists for the glucagon-like peptide 1 receptor.

Novo Nordisk Als

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

Pfizer

Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.

Merck Research Laboratories

Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.

Merck Research Laboratories

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

Merck Research Laboratories

Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.

University Of Texas At Dallas

Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.

Shionogi And

Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.

University Of Texas At Dallas

Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.

Tufts University

Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.

Novo Nordisk

Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.

Amgen

Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.

Pfizer

New beta-alanine derivatives are orally available glucagon receptor antagonists.

Novo Nordisk

Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.

Merck Research Laboratories

Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.

Conjuchem

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

Novo Nordisk

Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.

China Pharmaceutical University

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.

Sosei Heptares

Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology.

Nagasaki International University

Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.

Shanghaitech University

Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).

Sanofi-Aventis Deutschland

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Terns Pharmaceuticals

Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.

China Pharmaceutical University

Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.

China Pharmaceutical University

Optimization of peptide-based polyagonists for treatment of diabetes and obesity.

Novo Nordisk Research Center Indianapolis

A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.

China Pharmaceutical University

Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.

Sanofi-Aventis Deutschland

Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.

Sanofi-Aventis Deutschland

Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues.

University Of Copenhagen